Barry P. Flannelly - Apr 1, 2025 Form 4 Insider Report for INCYTE CORP (INCY)

Role
EVP & General Manager US
Signature
/s/ Elizabeth Feeney, Attorney-In-Fact
Stock symbol
INCY
Transactions as of
Apr 1, 2025
Transactions value $
$0
Form type
4
Date filed
4/3/2025, 04:52 PM
Previous filing
Mar 18, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INCY Common Stock Award $0 +11.2K +33.24% $0.00 44.7K Apr 1, 2025 Direct F1
transaction INCY Common Stock Award $0 +15K +33.48% $0.00 59.7K Apr 1, 2025 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on April 1, 2025. While Dr. Flannelly will retire from the Company on July 31, 2025, the earned shares will vest on November 30, 2025 in line with the retirement provisions of the plan. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, achievement of specified Opzelura performance goals. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 150% of the number of performance shares awarded.
F2 Represents the shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on April 1, 2025. The earned shares will vest on the third anniversary of the July 2, 2022 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, specified development, revenue and market-based (relative total shareholder returns compared to the Nasdaq Biotechnology Index) performance goals determined by the Issuers Compensation Committee in January 2022 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 150% of the number of performance shares awarded.
F3 This includes an aggregate of 59,689 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.